Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
The historical rank and industry rank for Tasly Pharmaceutical Group Co's Days Payable or its related term are showing as below:
SHSE:600535'
s Days Payable Range Over the Past 10 Years
Min: 65.76 Med: 92.37 Max: 110.34
Current: 77.61
During the past 13 years, Tasly Pharmaceutical Group Co's highest Days Payable was 110.34. The lowest was 65.76. And the median was 92.37.
SHSE:600535's Days Payable is ranked worse than 57.61% of 927
companies
in the Drug Manufacturers industry
Industry Median: 90.38
vs SHSE:600535: 77.61
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Tasly Pharmaceutical Group Co's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Tasly Pharmaceutical Group Co Days Payable vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Tasly Pharmaceutical Group Co's Days Payable distribution charts can be found below:
* The bar in red indicates where Tasly Pharmaceutical Group Co's Days Payable falls into.
Tasly Pharmaceutical Group Co Days Payable Calculation
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Tasly Pharmaceutical Group Co (SHSE:600535) has a Days Payable of 62.11 as of Mar. 2026. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Tasly Pharmaceutical Group Co and its competitors. This is 33% below median its historical median of 92.37. Over the past decade, Tasly Pharmaceutical Group Co's Days Payable has ranged from 65.76 to 110.34. According to the industry distribution chart, Tasly Pharmaceutical Group Co ranks #534 out of 927 companies in the Drug Manufacturers industry, placing it in the top 57.6%.
Is Tasly Pharmaceutical Group Co's Days Payable too high?
Tasly Pharmaceutical Group Co's current Days Payable of 62.11 is 33% below median its 10-year median of 92.37. Over the past 10 years, this metric has ranged from a low of 65.76 to a high of 110.34. The Drug Manufacturers industry median Days Payable is 90.38. Tasly Pharmaceutical Group Co's value of 62.11 is 31.3% below this industry median. Based on the distribution chart, Tasly Pharmaceutical Group Co ranks #534 out of 927 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Tasly Pharmaceutical Group Co has a GF Score™ of 79/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Tasly Pharmaceutical Group Co's Days Payable compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Tasly Pharmaceutical Group Co ranks #534 out of 927 companies for Days Payable. This places Tasly Pharmaceutical Group Co in the lower half of its industry. The industry median Days Payable is 90.38. Tasly Pharmaceutical Group Co's value of 62.11 is 31.3% below this benchmark. Historically, Tasly Pharmaceutical Group Co's own Days Payable has ranged from 65.76 to 110.34 over the past decade. While the company's 10-year median is 92.37 vs. the industry median of 90.38, Tasly Pharmaceutical Group Co has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Drug Manufacturers company?
The median Days Payable among Drug Manufacturers companies is 90.38, based on 927 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Tasly Pharmaceutical Group Co's current Days Payable of 62.11 is 31.3% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Tasly Pharmaceutical Group Co and its competitors. For the Drug Manufacturers industry, the median Days Payable is 90.38 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Tasly Pharmaceutical Group Co's current Days Payable is 62.11, which is 33% below median its own 10-year median of 92.37. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Tasly Pharmaceutical Group Co stock overvalued right now?
Based on GuruFocus' analysis, Tasly Pharmaceutical Group Co (SHSE:600535) is currently considered Fairly Valued. The stock's GF Value™ is ¥15.06, compared to a current price of ¥14.59 — trading 3.1% below its estimated fair value. The current Days Payable is 62.11, which is 33% below median its 10-year median of 92.37 and 31.3% below the Drug Manufacturers industry median of 90.38. Tasly Pharmaceutical Group Co's overall GF Score™ is 79/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For Tasly Pharmaceutical Group Co (SHSE:600535), the current Days Payable is 62.11 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Tasly Pharmaceutical Group Co (SHSE:600535) Overvalued in 2026?
Based on GuruFocus' analysis, Tasly Pharmaceutical Group Co stock appears to be undervalued.
The current stock price of ¥14.59 is trading 3.1% below its estimated GF Value™ of ¥15.06.
GuruFocus considers Tasly Pharmaceutical Group Co to be Fairly Valued.
Key valuation signals for SHSE:600535:
Days Payable: 62.11 (33% below median its 10-year median of 92.37)
GF Value™: ¥15.06 vs. price of ¥14.59 (3.1% below fair value)
Industry Position: 31.3% below the Drug Manufacturers median (#534 of 927)
No single metric tells the full story. See the SHSE:600535 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Tasly Pharmaceutical Group Co Business Description
Tasly Pharmaceutical Group Co Ltd is a China-based company engaged in the manufacturing and distribution of pharmaceutical products. Its herbal medicines include Tasly Cerebral Care Granules and Tasly ICP. Its chemical medicines comprise of Ketotifen Fumarate Tablets, Thiamphenicol Capsules, Glucurolactone Tablets and Sulpiride Tablets. Some of the other products offered by the company include PharmceuticalSubstances & API, HerbalExtract, and Concentrated Herbal Granules.
79GF Score
Get the complete analysis for SHSE:600535
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHSE:600535 has been successfully added to your 
